PI3K pathway is the dominant signal directly engaged by mutant KIT oncogenic cascade in GIST, therefore, PI3K inhibitors showed meaningful efficacy when combined with IM is ongoing in the clinical trials for the treatment of GIST [163]. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.